Absci Corporation ABSI
7.81 USD -0.64 (-7.57%)
As ofNov 16, 2026, 10:21 AM EST
7.29 Day range 8.15
2.24 52-week range 12.55
- YTD
- +123.78%
- 1 year
- +176.95%
News
benzinga.com Guggenheim Maintains Buy on Absci, Lowers Price Target to $14 Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $15 to $14.
seekingalpha.com Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
marketbeat.com Absci Q3 Earnings Call Highlights Absci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's…
zacks.com Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates Absci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
benzinga.com Absci Q3 2026 Earnings Call Transcript Absci (NASDAQ:ABSI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Absci Q3 EPS $(0.19) Beats $(0.20) Estimate, Sales $304.000K Miss $727.125K Estimate Absci (NASDAQ:ABSI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5 percent increase over losses of $(0.20) per share…
globenewswire.com Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month
globenewswire.com Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track…
seekingalpha.com Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcriptbenzinga.com Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14 Jefferies analyst Andrew Tsai initiates coverage on Absci (NASDAQ:ABSI) with a Buy rating and announces Price Target of $14.
benzinga.com Keybanc Maintains Overweight on Absci, Raises Price Target to $20 Keybanc analyst Scott Schoenhaus maintains Absci (NASDAQ:ABSI) with a Overweight and raises the price target from $16 to $20.
